Ultragenyx (RARE) came out with a quarterly loss of $1.40 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to loss of $2.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.45%. A quarter ago, it was expected that this biotechnology company would post a loss of $1.64 per share when it actually produced a loss of $1.52, delivering a surprise of 7.32%.Over the last four quarters, the company has s ...